SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-038161
Filing Date
2024-03-25
Accepted
2024-03-25 07:30:37
Documents
14
Period of Report
2024-03-25
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm249632d1_8k.htm   iXBRL 8-K 27342
2 EXHIBIT 99.1 tm249632d1_ex99-1.htm EX-99.1 14477
  Complete submission text file 0001104659-24-038161.txt   224686

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA apge-20240325.xsd EX-101.SCH 3045
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE apge-20240325_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apge-20240325_pre.xml EX-101.PRE 22379
17 EXTRACTED XBRL INSTANCE DOCUMENT tm249632d1_8k_htm.xml XML 3850
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

IRS No.: 880588063 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41740 | Film No.: 24776890
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)